Lenalidomide-associated hemolytic anemia

Leuk Lymphoma. 2015;56(9):2717-9. doi: 10.3109/10428194.2014.1003558. Epub 2015 Mar 2.

Authors

Ming Y Lim¹, Jay S Raval², Kristy L Richards¹, Joshua F Zeidner¹, Matthew C Foster¹

Affiliations

¹ a Division of Hematology/Oncology, Department of Medicine , University of North Carolina , Chapel Hill , NC , USA.
² b Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine , University of North Carolina , Chapel Hill , NC , USA.

PMID: 25644743
DOI: 10.3109/10428194.2014.1003558

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Anemia, Hemolytic / diagnosis
Anemia, Hemolytic / drug therapy
Anemia, Hemolytic / etiology*
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use
Lenalidomide
Leukemia, Myeloid, Acute / complications
Leukemia, Myeloid, Acute / drug therapy
Male
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents
Immunosuppressive Agents
Thalidomide
Lenalidomide